Esperion boosts sales of cholesterol-busting drugs
ANN ARBOR—The pharmaceutical firm Esperion Therapeutics Inc. (Nasdaq: ESPR) reported a rise in sales of its novel cholesterol-reducing drugs in the second quarter ended June 30 but still posted a …
Esperion names chief medical officer
ANN ARBOR—Officials at the Ann Arbor cholesterol drug developer Esperion Therapeutics Inc. (Nasdaq: ESPR) announced the appointment of JoAnne Micale Foody, MD, FACC, FAHA as chief medical officer, effective immediately. …
Esperion names new president, CEO
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) announced the appointment of Sheldon Koenig as president, CEO, and board member, effective immediately. He succeeds Tim Mayleben, whom company officials said “decided to …
Esperion targets another cholesterol-buster
ANN ARBOR—Esperion Therapeutics Inc., the Ann Arbor developer of novel cholesterol-fighting drugs, announced preliminary financial results and a new licensing agreement with Pittsford, N.Y.-based drug developer Serometrix. “As a result …
Esperion cholesterol-buster gets European OK
ANN ARBOR—The European Commission has approved the sale of new cholesterol-lowering drugs from Ann Arbor-based Esperion Therapeutics Inc. (Nasdaq: ESPR). Approved were Nilemdo, a tablet containing the new drug bempedoic …
Esperion has cash to last until new cholesterol drug produces profits
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR), the Ann Arbor-based pharmaceutical startup that’s about to introduce a new class of cholesterol-fighting drugs, reported a loss of $54.2 million or $2.01 a share …
Esperion posts first profit on royalty payments, nears market for cholesterol-busting drug
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR) has provided a development update for its lead drug candidate, bempedoic acid, and financial results for the first quarter ended March 31. “The potential of …